FIELD: medicine.
SUBSTANCE: invention relates to the use of ranibizumab in the treatment of pathological neovascularization of the retina of infants. This method for the treatment of infants with retinopathy of prematurity (ROP) includes the introduction of ranibizumab into the eye of a child in a dose of less than 0.25 mg.
EFFECT: invention provides treatment of infants with retinopathy of prematurity due to optimally selected doses of ranibizumab.
8 cl, 3 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF ANTAGONIST VEGF IN TREATMENT OF CHORIORETINAL NEOVASCULAR DISTURBANCES AND DISORDERS OF PENETRATION IN PEDIATRIC PATIENTS | 2014 |
|
RU2676274C2 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
| PRE-FILLED PLASTIC SYRINGE CONTAINING VEGF ANTAGONIST | 2015 |
|
RU2702748C2 |
| USE OF SIROLIMUS FOR TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH PERSISTENT EDEMA | 2017 |
|
RU2765728C2 |
| METHOD FOR TREATMENT OF EYE DISEASES | 2015 |
|
RU2771900C2 |
| METHOD OF TREATING EYE DISEASES | 2015 |
|
RU2722643C2 |
| NUTRICEUTICAL OPHTHALMOLOGICAL COMPOSITION FOR TREATMENT OF RETINAL PATHOLOGIES WITH A NEOVASCULAR COMPONENT | 2019 |
|
RU2806096C2 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| METHODS FOR TREATMENT OF EYE DISEASES | 2019 |
|
RU2776850C2 |
